GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » EPS (Diluted)

Panacea Acquisition II (Panacea Acquisition II) EPS (Diluted) : $0.06 (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II EPS (Diluted)?

Panacea Acquisition II's Earnings per Share (Diluted) for the three months ended in Dec. 2022 was $0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $0.06.

Panacea Acquisition II's EPS (Basic) for the three months ended in Dec. 2022 was $0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 was $0.06.

Panacea Acquisition II's EPS without NRI for the three months ended in Dec. 2022 was $0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $0.06.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Panacea Acquisition II EPS (Diluted) Historical Data

The historical data trend for Panacea Acquisition II's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II EPS (Diluted) Chart

Panacea Acquisition II Annual Data
Trend Dec21 Dec22
EPS (Diluted)
- 0.06

Panacea Acquisition II Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EPS (Diluted) Get a 7-Day Free Trial - -0.01 -0.01 0.03 0.05

Competitive Comparison of Panacea Acquisition II's EPS (Diluted)

For the Shell Companies subindustry, Panacea Acquisition II's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Acquisition II's PE Ratio Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Panacea Acquisition II's PE Ratio distribution charts can be found below:

* The bar in red indicates where Panacea Acquisition II's PE Ratio falls into.



Panacea Acquisition II EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Panacea Acquisition II's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1.428-0)/23.545
=0.06

Panacea Acquisition II's Diluted EPS for the quarter that ended in Dec. 2022 is calculated as

Diluted EPS (Q: Dec. 2022 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1.234-0)/23.545
=0.05

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Acquisition II  (NAS:PANA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Panacea Acquisition II EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Acquisition II (Panacea Acquisition II) Business Description

Traded in Other Exchanges
N/A
Address
357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103
Website
Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Executives
Ecor1 Capital Fund Qualified, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director, 10 percent owner 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc director, 10 percent owner 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano director C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni director C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott director, officer: Secretary C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen officer: Chief Financial Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout officer: Chief Investment Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon officer: Chief Operating Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103

Panacea Acquisition II (Panacea Acquisition II) Headlines